BRKR
Bruker Corporation44.96
-0.71-1.55%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Cost savings hiked to $140M
Q&A unpacked Q4 margin miss—idiosyncratic mix, delayed tariffs, extra FX headwinds—but management boosted cost savings to ~$140M annualized, half fueling gross margin gains for 250-300bps op expansion. No end-market snapback: biopharma/semi low-single growth, U.S. academic bookings down high-teens last year and flat ahead, BioSpin lagging on slim UHF NMR revenue. China stays flat; molecular diagnostics pulls through strong. Q1 organic dips mid-single on comps. BioSpin lags. Cautious tone persists; watch academic thaw, margin ramp.
Key Stats
Market Cap
6.83BP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
10-K
FY2025 results
Bruker posted FY2025 revenue of $3.44B, up 2.1% y/y yet down 0.2% at CER amid softer industrial/semiconductor demand, with Q4 strength from seasonality and hospital/clinical markets offsetting organic declines. BSI CALID surged 10.7% on ELITechGroup and optics/microbiology gains, while BSI NANO dipped 1.3% on academic weakness despite NanoString; BioSpin fell 3.0% on fewer GHz NMR sales, BEST 4.3% on MRI softness. Gross margins contracted to 45.9% from tariff hikes and FX headwinds, operating income plunged to $68M (2.0%) after $96M goodwill impairments and $77M restructuring. Debt fell to $1.9B post preferred issuance, free cash flow $43M. Q4 accelerated via budgeting cycles. U.S. academic funding cuts threaten quarterly momentum.
8-K
Director retires; dividend declared
Bruker disclosed director Dr. Cynthia M. Friend's retirement at the 2026 Annual Meeting, effective post her current term ending then; no disagreements noted. Jack Phillips shifted from Class III to Class II, service uninterrupted since January 2026. Board declared $0.05 quarterly dividend, payable April 7 to March 23 record holders. Board stays steady.
8-K
Q4 flat, FY26 growth eyed
Bruker reported Q4 revenues flat at $977.2M amid 5% organic decline, yet beat expectations with non-GAAP EPS of $0.59. Full-year FY25 revenues hit $3.44B (up 2% YoY), but GAAP loss per share was $(0.15) after $127M impairments and $77M restructuring. Management eyes FY26 rebound: $3.57-3.60B sales, non-GAAP EPS $2.10-2.15. Margins lagged.
8-K
Preliminary Q4 revenue $965M-$970M
Bruker shared preliminary Q4 2025 revenue of $965M-$970M at the J.P. Morgan Healthcare Conference on January 12, 2026, with Scientific Instruments book-to-bill above 1.0. For 2026, it eyes flat to low-single-digit organic revenue growth, 250-300 bps non-GAAP operating margin expansion, and double-digit non-GAAP EPS growth versus 2025. Figures await audit. Risks loom from market volatility.
8-K
Bruker adds diagnostics expert Phillips
Bruker expanded its board to eleven directors and appointed diagnostics veteran Jack J. Phillips, effective January 1, 2026, until the 2027 annual meeting. Phillips brings 30+ years leading firms like Roche Diagnostics and Accelerate Diagnostics. His expertise bolsters Bruker's push into infectious disease diagnostics. Committee assignments pending.
ABT
Abbott Laboratories
126.86-1.61
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BSX
Boston Scientific Corporation
92.95+0.76
DHR
Danaher Corporation
224.70-3.83
LAB
Standard BioTools Inc.
1.49-0.02
MASI
Masimo Corporation
134.52-2.88
PACB
Pacific Biosciences of Californ
2.02-0.10
SYK
Stryker Corporation
351.69-3.62
TMO
Thermo Fisher Scientific Inc
570.16-5.75